🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Chairing session on high sensitivity troponins: state of the art slides from Christian Mueller including ESC 0/1 algorithm #ESCCongress

Conclusions regarding Myocardial Infarction following non cardiac surgery per PJ Devereaux #ESCCongress

#women do worse after #STEMI even with less obstructive CAD as demonstrated in their JAMA paper by Raffaele Bugiardini #ESCCongress Leslee Shaw Silvia Castelletti MIЯVΛƬ #IC C. Michael Gibson MD

The late-breaking science continues! COMPLETE: staged complete revasc superior to culprit only revasc in reducing CV death/MI/revasc in patients with STEMI and multivessel CAD #ESCCongress

I was in the back outside! There was applause with this slide at #ESCCongress for the new addition of SGlT2i's in the management of HFrEF, even in non-diabetics!! Giuseppe Galati Mihai Trofenciuc Paola Morejón Barragán Harriette Van Spall, MD MPH 🇨🇦

#ESCCongress Paragon-HF Trial 💊: angiotensin-neprilysin ❌ did not result in ⬇️ in HF hospitalization or CV death in patients with #HFpEF! @visualmedapp #CardioTwitter #ACCFIT American College of Cardiology #ACCWIC Houston Methodist Cardiovascular Fellowships Houston Methodist CV DeBakey CV Education - World Class CV Training

More stunning results published in NEJM. ISAR REACT 5. Prasugrel vs ticagrelor for ACS: Prasugrel reduces death/MI/stroke at 1 year. No difference in bleeding. Wow. #ESCcongress2019

In an RCT of 31,492 patients with suspected acute coronary syndrome, a rule out pathway using a hs-TnI risk stratification threshold of 5ng/L reduced length of stay by 3.3hrs (57% ⬆️ in ED discharge) with no evidence of harm at one year #ESCCongress #HiSTORIC #troponin

Results from Rilonacept Phase 2 trial presented at AHA 2019 show rapid resolution of recurrent pericarditis episodes and improvement in quality of life scores. Full poster here: clinicaltrialresults.org/Slides/AHA%202… Sponsored by an unrestricted educational grant from Kiniksa

TWILIGHT-ACS slides presented at #AHA19 demonstrate that, in patients with NSTE-ACS undergoing PCI, continuing treatment with ticagrelor alone lowers risk of bleeding without increasing the risk of an ischemic event over one year. Full slide deck: clinicaltrialresults.org/Slides/AHA%202…

DAPA-HF Substudy slides presented at #AHA19 demonstrate that Dapagliflozin could potentially be used to treat HFrEF in patients with and without diabetes. Full slide deck: clinicaltrialresults.org/Slides/AHA%202…

ORION-10: Inclisiran, a twice-yearly siRNA injectable reduced LDL-cholesterol levels by 58% in pts with ASCVD and elevated LDL compared with placebo. Full slides are posted here: clinicaltrialresults.org/Slides/AHA%202… Sponsored by an independent educational grant from The Medicines Company

EVAPORATE Trial slides presented at #AHA19 suggest Icosapent Ethyl in addition to statin therapy provides benefit on plaque characteristics. Full slide deck: clinicaltrialresults.org/Slides/AHA%202…

Patients w/ stable CAD & moderate-severe ischemia experiencing angina had early & sustained improvements in angina and QoL w/ an invasive strategy compared to OMT in the ISCHEMIA Quality of Life data presented at #AHA19 Review the full slides here: clinicaltrialresults.org/Slides/AHA%202…

In pts with recent ischemic stroke or TIA & evidence of atherosclerotic disease, a target of <70 mg/dL LDL cholesterol had lower risk of subsequent CV events compared to pts w/ an LDL cholesterol target of 100+/-10 mg/dL #AHA19 View the full deck here: clinicaltrialresults.org/Slides/AHA%202…

Dr. Uma Sinha Presents: Differential Transthyretin Binding, Kinetic Stability and Additive Ex Vivo Stabilization by AG10 Compared to Tafamidis View the full poster here: clinicaltrialresults.org/Slides/AHA%202… Sponsored by an unrestricted educational grant from Eidos Therapeutics

ORION-9 slides presented at #AHA19 demonstrate a highly significant lowering of LDL-C relative to placebo with Inclisiran for patients with Heterozygous Familial Hypercholesterolemia. Full deck here: clinicaltrialresults.org/Slides/AHA%202…

Dr. Maura Marcucci and Dr. YAZ, MD discuss results from POISE 3 trial for perioperative BP management in non-cardiac surgery. Interview link here: bit.ly/35BYjoe #cardiology #surgery

ADAPT-TAVR trial: in TAVR patients, edoxaban similar to DAPT in incidence of leaflet thrombosis on CT scans, no difference in rate of new cerebral thromboembolism. Download full slides from ADAPT-TAVR here: bit.ly/3DSDBxn #cardiology #tavr

GIPS-IV trial: sodium thiosulfate after MI not associated with reduction in infarct size. Download slides from GIPS-IV here bit.ly/3DCTcke #cardiology